merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks, including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for potentially better treatments</answer>
<question_number>3</question_number>
<answer>There is no correlation between amyloid plaque removal and clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>It may raise concerns about Kisunla's safety due to higher rates of swelling and bleeding</answer>
<question_number>5</question_number>
<answer>Patients can stop treatment after amyloid plaques are cleared, potentially reducing overall cost</answer>
<question_number>6</question_number>
<answer>It may discourage participation in trials for other treatments</answer>
<question_number>7</question_number>
<answer>Patients can stop treatment after amyloid is cleared, reducing cost, inconvenience, and risk of side effects</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Patients with intermediate tau levels declined more slowly than those with high levels</answer>